Management of pancreatic neuroendocrine neoplasms in Japan's rapidly aging society

DOI Web Site 30 References
  • FUJIMORI Nao
    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University
  • MURAKAMI Masatoshi
    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University
  • MATSUMOTO Kazuhide
    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University
  • OHNO Akihisa
    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University
  • TERAMATSU Katsuhito
    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University
  • UEDA Keijiro
    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University
  • ITO Tetsuhide
    Neuroendocrine Tumor Centre, Fukuoka Sanno Hospital Department of Gastroenterology, Graduate School of Medical Sciences, International University of Health and Welfare
  • OGAWA Yoshihiro
    Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University

Bibliographic Information

Other Title
  • 超高齢社会における膵神経内分泌腫瘍診療

Description

<p>The incidence of pancreatic neuroendocrine neoplasms (PanNENs) has been increasing worldwide due to improved disease recognition and advances in diagnostic modalities such as computed tomography and endoscopic ultrasound. The number of older adult patients with PanNENs is expected to increase in Japan's rapidly aging society. Therefore, it is important to establish treatment strategies for older adult patients. The only curative treatment for PanNENs is surgical resection, which can be safely performed in older adult patients when selected appropriately. Depending on age, comorbidities, and tumor size, nonsurgical management, such as observation and systemic therapy, should also be considered. Systemic therapies, including somatostatin analogs, targeted therapies, cytotoxic chemotherapy, and peptide receptor radionuclide therapy, are available for patients with unresectable or metastatic pancreatic neuroendocrine tumors (PanNETs). When administering these therapies to older adult patients with PanNETs, it is important to balance the treatment, and the adverse events which can be linked to it, with the patient's comorbidities and cognitive function. Further studies on older adult patients with PanNETs are warranted to establish an optimal treatment strategy.</p>

Journal

  • Suizo

    Suizo 39 (1), 33-42, 2024-02-29

    Japan Pancreas Society

References(30)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top